On March 4, the investment community reported that Zhongbo Ruikang (Shanghai) Biotechnology, a domestic high-quality cell preparation intelligent tool systematization overall solution service provider, was recently completedNearly 100 million yuan in Series B financing
This round of financing consists of:Daotong Investment led the investment, followed by Qikun** and Jinjue Investment, old shareholderHi-Tech Xinjun, Yuanyi Investment and Innovation Factory continue to increase, Yuanshi Investment and others served as financial advisors for this round of financing. The funds raised will be mainly used to build a modern production system, enhance R&D strength and global registration certificate capabilities across the board, and expand key global markets at a high speed.
Since the launch of the first batch of self-developed products in 2021, the company has a strong development momentum in the field of cell preparation tools. Adhering to the design concept of "serial management", the company has expanded from the initial 2 series of products to the current 7 series of products, covering the whole process of cell preparation. This is not only a strong proof of Zhongbo Ruikang's technological innovation and continuous research and development, but also demonstrates the company's firm commitment to improving the productization ability and quality of automatic cell preparation systems.
Zhongbo Ruikang is not only a R&D and manufacturer of equipment, but also a technical service expert who provides innovative and comprehensive solutions, with the ability to produce GMP-level consumables and liquid products, as well as the registration ability of the corresponding product authority. This enables Zhongbo Ruikang to provide one-stop comprehensive solutions covering equipment, consumables and liquid reagent products, provide excellent fully closed cell preparation tool solutions for bio-innovative pharmaceutical companies, and help China's high-quality development in the field of cells and genes.
After 2022, Zhongbo Ruikang has shifted from catching up to independent R&D and innovation, and has become one of the first-class echelons of CGT upstream tools in China, and has reached cooperation with more than 100 companies in just 2 years, including cell and gene drug R&D enterprises, hospital translational medicine research centers, and medical anti-aging services and health care platforms. This extensive partner network not only highlights the wide acceptance and trust of Zhongbo Ruikang products in the market, but also verifies that its products and services can meet the diverse needs of different industries and different types of customers.
The process transformation from manual to automated and closed production system has become the consensus of CAR-T pharmaceutical companies in cell preparation. The use of fully enclosed automation tools is the only way for the development of the CGT industry.
Based on this, Zhongbo Ruikang launched the Wukong series of cell preparation all-in-one machines. The equipment can complete the entire process of CAR-T cell preparation, including key steps such as cell isolation, sorting, gene modification, culture, formulation and dispensing. It has a wide range of applications, including IIT clinical research, cell ** technology of FASTCAR process, multi-center clinical trials, future high-speed market at the hospital bedside, etc., and can be fully adapted to various cell preparation scenarios.
For access to this round of financing,Wei Dongbing, founder of Zhongbo Ruikang"Zhongbo Ruikang will continue to leverage its excellent fully enclosed cell preparation tool solutions and its global business network to provide high-quality services to biopharmaceutical companies around the world and promote the global development of the field of cells and genes." In the future, Zhongbo Ruikang will continue to uphold the spirit of innovation and bring more innovative solutions to the cell and gene tool industry to achieve its strategic goal of globalization. ”
Qi Sun, founding managing partner of Daotong Investments"With the emergence of new technologies and means of cell genetics, we believe that it is particularly important to continuously reduce CMC costs and realize the automation and traceability of the production process. However, the underlying manufacturing equipment of CGT in China has been monopolized by import enterprises for a long time, and the gap between supply and demand is large, high, and the order cycle is long, which is easily affected by emergencies, which has caused the problem of "stuck neck" in the industry and limited the long-term healthy development of China's CGT industry. Therefore, China's cell industry urgently needs to embark on the road of industrial technology and equipment localization. Coupled with the introduction of the implementation plan of the 14th Five-Year Plan in the medical field, China is accelerating the realization of domestic substitution of equipment in the cell industry. The founding team of Zhongbo Ruikang has been deeply involved in the famous Fortune 500 companies in the field of medical devices for 13 years, and then took over as the head of Meitianyi China, and has rich experience in the R&D and industrialization of equipment and consumables, especially multi-item and multidisciplinary consumables. We look forward to the completion of this round of financing to make more significant achievements in R&D and marketing, and move forward towards the goal of reducing costs for the CGT industry and benefiting patients." ”
Chen Yicheng, managing partner and general manager of Qi Kun**He said: "Zhongbo Ruikang is the R&D and manufacturer of China's head cell preparation all-in-one machine equipment, with a number of domestic first-of-its-kind products. The cell preparation machine is the most important upstream equipment for cell drugs, and there is a serious lack of localized tools. We firmly believe that the all-in-one machine developed by Zhongbo Ruikang can effectively make up for the gap in this field in China, realize domestic substitution, greatly reduce the R&D and production costs of cell drugs, and benefit the majority of patients. ”
Shen Jinyao, founding partner of Jinjue Investment"As a leading company in the field of life sciences, we are honored to be part of its team of financing shareholders. With Jinjue's rich investment experience and solid industry insight, we firmly believe that with the joint efforts, Zhongbo Ruikang will usher in a broader development space and unlimited possibilities. We see this investment as an opportunity to be deeply involved in the forefront of the life sciences field, and it is also an important step to promote the continuous extension of the value chain. ”
Zhu Jin, Managing Director of Hi-Tech Xinjun"In the future, the requirements for stable, safe and efficient production of cell drugs will inevitably force enterprises to gradually switch from the current complicated, lengthy and high-consumption manual operations to semi-automatic and fully automatic production processes," he said. As a leading enterprise in CGT intelligent tools, Zhongbo Ruikang has achieved a good first-mover advantage by virtue of its profound accumulation in the industry and the pioneering spirit of the team. We are pleased to continue to support Zhongbo Ruikang in this round, support Zhongbo Ruikang to develop into a leader in CGT intelligent tools, and accelerate the development and commercialization of CGT drugs." ”
Gao Ying, head of medical and health care of Yuanyi InvestmentHe said: "Yuanyi continues to pay attention to the direction of emerging technologies such as CGT and the actual demand for upstream equipment, since Yuanyi invested in Zhongboruikang, the company's product iteration and upgrading has been rapid, continuously injecting new development momentum into the domestic CGT industry, and the future will usher in the demand explosion of production transformation and process landing." We look forward to the company's team continuing to promote the localization process of cell preparation systems, bringing more empowerment to the industry, and enabling new technologies to benefit the majority of patients more quickly." ”
Xiao Hai, Investment Director of Sinovation Works"Since the investment in Sinovation Works, the company has made great strides and established a full range of cell tools. During the downward cycle of the industry, the company achieved continuous revenue growth against the wind and successfully opened up overseas markets. With the gradual warming of the cell and gene market, the company's value as an industry infrastructure will be highlighted, helping to quickly launch and optimize the cost of innovation** to benefit more patients. ”